Charles H. Chevalier

I'll research this attorney before drafting.

Let me verify the firm context, the tracked cases, and PTAB involvement.

Charles H. Chevalier — patent litigation summary

Focus areas. Chevalier is a partner in the intellectual property group of FBT Gibbons LLP (Newark, NJ), where his practice centers on pharmaceutical and life-sciences patent litigation—particularly Hatch-Waxman/ANDA disputes, competitor drug litigation, licensing and IP transactional work, and opinion/pre-suit counseling. Firm and directory profiles describe counseling on beta-blockers, oral contraceptives, ADHD therapies and immunosuppressants, and Chambers notes particular life-sciences expertise (Chambers USA; fbtgibbons.com). He is not, on the available record, a Wi-Fi/standards or software-focused litigator; his identified technical background is chemical/biochemical, including prior work as a research biochemist in the pharmaceutical industry before law practice.

Side preference. The tracked dataset is narrow and one-sided: three appearances, all on the defendant side as local counsel (Halozyme, Inc. v. Merck Sharp & Dohme Corp./LLC; Merck Sharp & Dohme LLC v. Halozyme, Inc.). Public docket records show a broader practice than the three tracked matters suggest, including plaintiff-side ANDA work as counsel of record for American Regent, Inc. (a Daiichi Sankyo subsidiary) in D.N.J. actions against Cipla and Somerset Therapeutics. On the whole he appears to be a defense-leaning brand/generic litigator rather than an NPE/PAE plaintiff's lawyer; there is no indication of NPE-side prosecution or assertion work.

Firm context. He has practiced at Gibbons P.C. and, following the January 1, 2026 combination of Gibbons with Frost Brown Todd LLP, at FBT Gibbons LLP, where he remains in Newark. He serves on the New Jersey Intellectual Property Law Association board (Secretary 2023, Treasurer 2024, Vice President 2025, President-Elect 2026). No prior-firm history was found in the sources reviewed.

Notable matters. The tracked Halozyme/Merck matters are part of the ongoing Merck–Halozyme dispute over subcutaneous Keytruda (pembrolizumab) and Halozyme's PH20 hyaluronidase patents; in Halozyme, Inc. v. Merck Sharp & Dohme Corp., No. 2:25-cv-03179 (D.N.J.), Chevalier appeared for Merck and successfully pressed that the named defendant entity no longer existed following the 2022 merger into Merck Sharp & Dohme LLC, resulting in a stipulation substituting the correct entity. Related PTAB post-grant reviews filed by Merck against Halozyme's patents produced final written decisions in May 2026 holding claims of the '600 and '262 patents unpatentable (Venable BiologicsHQ), though the petitions in that dispute were prosecuted by other counsel and Chevalier's own PTAB role is not verified. IAM's New Jersey Patent 1000 analysis also credits him and David De Lorenzi with the defense win for EMD Serono, Pfizer and Novartis in Biogen's interferon-beta '755 patent case—a five-week D.N.J. jury trial finding the patent anticipated, with the Federal Circuit reinstating the verdict, 976 F.3d 1326 (2020), and certiorari denied. That attribution rests on the IAM directory entry rather than a court filing I could verify.

PTAB/IPR experience. No regular PTAB practice is established. He writes on PTAB decisions (e.g., Lightricks v. Plotagraph, § 315(b) time bar), but directory coverage identifies his colleague Christopher Strate—not Chevalier—as the firm's IPR specialist.

Bar/education. J.D., Seton Hall University School of Law (cum laude); B.A., Swarthmore College. Admitted in New Jersey and New York, before the U.S. District Courts for the S.D.N.Y. and E.D.N.Y., and registered before the USPTO.